Tretazicar is primarily used in the field of cancer therapy as a prodrug. It is designed to be activated specifically within hypoxic (low oxygen) environments, which are commonly found in solid tumors. Upon activation, it releases a cytotoxic agent that targets and destroys cancer cells, making it particularly effective in treating tumors with poor blood supply. This selective activation helps minimize damage to healthy, oxygen-rich tissues, reducing side effects compared to traditional chemotherapy. Tretazicar is often explored in combination with other treatments to enhance its efficacy in combating resistant or aggressive cancers.